Lymphoma Clinical Trials in Chicago

Showing 61-80 of 306 trials

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

NCT05602363

This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.

B-cell MalignancyChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma+5 more

Carna Biosciences, Inc.120 participantsStarted Aug 2023

Orange, California, United States • Miami Beach, Florida, United States • Tampa, Florida, United States +10 more locations

RECRUITINGPHASE32.2 miles

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

NCT06470451

To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).

CTCL/ Mycosis FungoidesCTCLMycosis Fungoides+1 more

Soligenix80 participantsStarted Jan 2025

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • San Diego, California, United States +14 more locations

AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL

Lymphoma Trials in Other Cities

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 1 Study of of Anti-CD7 Allogeneic CAR-T Cell Therapy (WU-CART-007) in Patients With Relapsed or Refractory T-ALL/LBL

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

MB-105 in Patients With CD5 Positive T-cell Lymphoma

Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma

Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Other Conditions in Chicago